UNSPSC 51371902: Betacetylmethadol

This classification denotes an opioid receptor agonist with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 905GLN509G, chemically known as 3-heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3r,6r)-(-)- but generally known as betacetylmethadol, which bears US NIH Compound Identifier 62710. European Medicines Agency schedules Betacetylmethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05792MIG.

UNSPSC 51371902 Betacetylmethadol, a Commodity code, nominally identifies a synthetic opioid pharmaceutical but shows little recent state and local procurement activity directly aligned with that product. The three recent opportunities tagged to this code involve naloxone procurement, a therapeutic pharmacy initiative focused on direct-to-manufacturer prescription programs, and multi-source generic pharmaceutical and over-the-counter product distribution through a cooperative purchasing vehicle—none of which address betacetylmethadol specifically. The mismatch suggests either a data-tagging inconsistency in the source systems or that this code is used more broadly to encompass opioid-related pharmaceutical procurement than its narrow product name implies. State and local buyers in this space include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances managing pharmaceutical supply chains for public health and employee benefit programs.

The three opportunities span Florida, Texas, and a Minnesota-anchored multistate cooperative purchasing network serving Oregon and other participating jurisdictions. Seminole County, Florida (IFB 60459723LAS, response deadline July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bid with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission (RFI HHS0017013, posted April 3, 2026) issued an exploratory Request for Information on direct-to-manufacturer prescription contracting to gather vendor capabilities before issuing a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration (RFP S1070000015802, response deadline March 26, 2026), solicited manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across state and local government facilities, with awards effective July 1, 2026, and pricing weighted 75 percent in the evaluation.